{"id":"mgn1703-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4297776","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MGN1703 is a synthetic oligodeoxynucleotide containing unmethylated CpG motifs that bind to TLR9 on immune cells, particularly B cells and plasmacytoid dendritic cells. This activation triggers innate immune signaling pathways that promote interferon-alpha production and enhance both innate and adaptive anti-tumor immune responses. It is designed to be used as an immunotherapeutic agent to boost the body's natural anti-cancer defenses.","oneSentence":"MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:12.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (Phase 3)"},{"name":"Non-small cell lung cancer (Phase 2)"}]},"trialDetails":[{"nctId":"NCT02668770","phase":"PHASE1","title":"Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-11","conditions":"Advanced Cancers, Melanoma","enrollment":28},{"nctId":"NCT02077868","phase":"PHASE3","title":"Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment","status":"UNKNOWN","sponsor":"Mologen AG","startDate":"2014-09","conditions":"Metastatic Colorectal Cancer","enrollment":540},{"nctId":"NCT02200081","phase":"PHASE2","title":"Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC","status":"COMPLETED","sponsor":"Mologen AG","startDate":"2014-03","conditions":"Small Cell Lung Cancer","enrollment":103},{"nctId":"NCT02443935","phase":"PHASE1, PHASE2","title":"Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-04","conditions":"HIV","enrollment":12},{"nctId":"NCT01208194","phase":"PHASE2","title":"Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma","status":"COMPLETED","sponsor":"Mologen AG","startDate":"2010-06","conditions":"Advanced Colorectal Carcinoma","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dSLIM"],"phase":"phase_3","status":"active","brandName":"MGN1703 treatment","genericName":"MGN1703 treatment","companyName":"Mologen AG","companyId":"mologen-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MGN1703 is a Toll-like receptor 9 agonist, classified as an agonist drug. It is being studied in clinical trials for various conditions, including advanced cancers, melanoma, and metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}